mobilemenuClose menu
New research study on chronic breathlessness - Better-B

New research study on chronic breathlessness - Better-B


BETTER-B is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No.  825319.

The new research trial (the BETTER-B study) is being carried out to assess whether a drug called Mirtazapine is effective in treating chronic breathlessness.

Mirtazapine is well known to doctors and is currently used to treat other medical conditions.

If you have pulmonary fibrosis or another form of interstitial lung disease (ILD) you may be eligible to join the trial. COPD patients can also take part. Participants will take either Mirtazapine or a placebo tablet for 8 weeks and will be interviewed 6 times by researchers. These interviews can be done by phone or video call. There will be no need to visit a hospital.

The study is being led by Professor Irene Higginson at King’s College London and being undertaken in the UK, Ireland, Germany, Italy and Poland.

If you are interested in taking part in the trial or finding out more about BETTER-B, please contact the team at

For further news and updates on the programme, please visit our website ( and subscribe to our newsletter.